Vaginal dryness and GSM — the most underreported menopause symptom
Genitourinary Syndrome of Menopause (GSM) — vaginal dryness, burning, painful sex, and urinary symptoms — affects up to 50% of postmenopausal women. Unlike hot flashes, it does not improve with time. It gets worse. And it is almost never discussed, almost never treated, and entirely reversible with the right intervention. Rose covers everything.
Rose
"GSM is the menopause symptom I find most consistently undertreated in my research — and the one women most consistently manage in silence. The statistics are stark: fewer than one in four women with GSM ever discusses it with a doctor. Meanwhile the tissue is getting thinner, the pH is rising, and symptoms that are entirely reversible with local estrogen are being accepted as permanent. This page is for the women who have been quietly managing this. You do not have to."
The scale of this
50%
of postmenopausal women have GSM symptoms — rising with age
<25%
of women with GSM symptoms ever discuss them with a doctor
100%
reversible with local vaginal estrogen — this is not something to accept
Key takeaways
✓GSM (Genitourinary Syndrome of Menopause) is the umbrella term for vaginal dryness, burning, painful sex, and urinary symptoms — they share the same estrogen-deficiency root cause
✓Unlike hot flashes, GSM does not improve with time — it progressively worsens without treatment as tissue continues to thin
✓Local vaginal estrogen is the most effective treatment — it reverses tissue thinning, restores Lactobacillus ecology, reduces painful sex, and prevents recurrent UTIs
✓Minimal systemic absorption at standard doses — local vaginal estrogen is safe for most women including many with breast cancer history
✓Women on systemic HRT often still need local vaginal estrogen — systemic doses may be insufficient for full urogenital tissue restoration
✓Vaginal moisturisers (hyaluronic acid) used regularly and lubricants for sex are important adjuncts — but are not substitutes for local estrogen
✓GSM is massively underreported and undertreated — you may need to raise it specifically. Your doctor may not ask.
What GSM actually is — the full symptom picture
GSM is not just vaginal dryness — it is a constellation of symptoms from the same tissue changes across the vagina, vulva, urethra, and bladder.
💧
Vaginal dryness
A persistent dryness, roughness, or sandpaper sensation — present all the time, not just during sex. Often described as uncomfortable to sit, walk, or exercise. The vaginal walls have lost their natural lubrication because estrogen-dependent Bartholin glands and vaginal transudate are no longer functioning adequately.
🔥
Burning and irritation
A burning or stinging sensation in the vaginal or vulval area — sometimes constant, sometimes triggered by clothing, heat, or activity. The thinned, drier tissue is hypersensitive and inflamed.
💔
Painful sex (dyspareunia)
Pain during or after sexual intercourse — from mild discomfort to severe, tearing pain. The loss of lubrication and vaginal wall elasticity means penetration causes friction against already inflamed tissue. One of the most impactful GSM symptoms for quality of life and relationships — and one of the most treatable.
🔵
Urinary urgency and frequency
The need to urinate suddenly and urgently, voiding more frequently than before. Estrogen receptors in the bladder and urethra mean the same tissue changes affect urinary control. Urgency that interrupts sleep, work, and daily activities.
🔴
Recurrent UTIs
Urinary tract infections that keep returning — driven by the thinner, less protected urethral tissue and the vaginal microbiome shift that allows E. coli to colonise the periurethral area. Often treated with repeated antibiotics without addressing the root cause.
🌸
Vulval itching and sensitivity
Itching of the vulval skin — the external tissue around the vaginal opening — that is persistent and not explained by infection. The vulval skin has the same estrogen receptor density as the vaginal walls and undergoes the same thinning and drying.
📉
Loss of arousal and orgasm changes
Reduced genital sensation, longer time to arousal, or difficulty reaching orgasm. Estrogen receptors in the clitoris and genital tissue mean their loss reduces sensitivity and blood flow. Testosterone decline compounds this.
Why it happens — four mechanisms
🧬
Estrogen maintains vaginal tissue — its loss is immediate
The vaginal epithelium — the multi-layer cell lining of the vaginal walls — is directly estrogen-dependent. Estrogen stimulates the maturation and proliferation of squamous epithelial cells, maintains the thickness of the vaginal walls (normally 15-20 cell layers thick), promotes glycogen production in these cells, and supports the rich blood supply that provides vaginal transudate (the natural lubrication). Within weeks of estrogen loss at menopause, these processes slow: the cell layers thin (sometimes to just 3-5 layers), glycogen falls, transudate reduces, and the vaginal pH rises from its protective 3.5-4.5 to 5.0-7.5.
🦠
The Lactobacillus-estrogen-glycogen chain
Vaginal health depends on a specific ecology: estrogen stimulates glycogen production → glycogen feeds Lactobacillus → Lactobacillus produces lactic acid → lactic acid maintains the acidic pH that protects against pathogens. When estrogen falls, glycogen falls, Lactobacillus declines, pH rises, and the protective ecology collapses. The resulting vaginal dysbiosis allows anaerobic bacteria, E. coli, and other organisms to colonise — producing the altered odour, discharge, and infection risk of GSM.
📈
GSM is progressive — it worsens without treatment
Unlike hot flashes, which often improve over time as the body adapts to lower estrogen levels, GSM does not self-resolve. Without treatment, the tissue continues to thin, the pH continues to rise, and symptoms progressively worsen. Many women who had minimal vaginal symptoms in perimenopause find GSM becoming severely symptomatic by their late 50s and 60s. This progressive nature makes early treatment — ideally in perimenopause before significant tissue change has occurred — significantly more effective than waiting.
🤫
The silence problem — GSM is massively underreported
Studies consistently show that fewer than 25% of women with GSM symptoms discuss them with their doctor — despite the symptoms significantly affecting their quality of life, relationships, and sexual function. Women do not raise it because they consider it an inevitable consequence of ageing, because they feel embarrassed, or because they do not know it is treatable. Doctors do not ask. The result is that one of the most common and most treatable menopause conditions is left untreated in the vast majority of women who have it.
What actually helps — evidence graded
🌸
Local vaginal estrogen — the gold standard treatment
Strong evidence
Local vaginal estrogen is the most effective treatment for GSM — directly restoring the estrogen-dependent tissue that has been lost. Applied locally, it reverses vaginal wall thinning, restores glycogen production, re-establishes Lactobacillus-dominant microbiome, lowers pH back to protective range, and restores the vascular blood supply that produces natural lubrication. The evidence base is extensive and the safety profile is excellent — including for most women with breast cancer history.
Key points
• Reverses vaginal wall thinning — cell layer thickness recovers with sustained use
• Lowers vaginal pH to protective range — restores the Lactobacillus ecology
• Restores natural lubrication and arousal capacity
• Reduces painful sex — often completely resolving dyspareunia within 3-6 months
• Reduces recurrent UTI frequency by addressing periurethral tissue vulnerability
• Minimal systemic absorption — blood estrogen levels remain in the postmenopausal range
• Safe for most women with breast cancer history at low doses — endorsed by major oncology guidelines
How to use this
Vaginal estradiol pessary (Vagifem 10 mcg or Vagirux) or estriol cream (Ovestin 0.1%). Initial loading: insert/apply daily for 2 weeks, then twice weekly ongoing. Must be continued indefinitely — tissue reverts within weeks of stopping. Takes 4-12 weeks for symptom improvement; full tissue restoration takes 3-6 months. Ask your GP specifically — GSM is commonly undertreated and vaginal estrogen may not be offered without prompting.
💊
Ospemifene (Senshio) — the oral option for GSM
Strong evidence
Ospemifene is a selective estrogen receptor modulator (SERM) taken as a daily oral tablet. It acts as an estrogen agonist in vaginal tissue — improving vaginal cell maturation and reducing dyspareunia — while being estrogen-neutral or antagonist in breast tissue. Useful for women who cannot or prefer not to use vaginal products. Licensed specifically for moderate-to-severe dyspareunia from GSM in postmenopausal women.
Key points
• Effective for vaginal dryness and painful sex — comparable to local estrogen for dyspareunia
• No vaginal application required — daily tablet
• Estrogen-neutral or protective in breast tissue — relevant for women with breast cancer concerns
• Also has beneficial effects on bone density (SERM mechanism)
• Can be used alongside systemic HRT
How to use this
Ospemifene 60mg daily oral tablet. Prescription required — not widely known or offered. Ask your GP or gynaecologist. Takes 4-12 weeks for full effect. Not suitable during pregnancy. May cause hot flashes in some women as a side effect.
💧
Vaginal moisturisers — regular maintenance between episodes
Moderate evidence
Vaginal moisturisers are not lubricants — they are designed for regular use (2-3 times weekly) to maintain baseline vaginal moisture and reduce the chronic dryness and discomfort of GSM. They work by binding water to vaginal tissue and temporarily restoring moisture without addressing the underlying tissue atrophy. Most effective as an adjunct to local estrogen rather than a replacement for it.
Key points
• Hyaluronic acid-based formulations (Yes VM, SYLK) have the best evidence — hyaluronic acid binds water in vaginal tissue
• Reduces baseline dryness and irritation between lubricant use
• Can be used during the loading period while local estrogen is building effect
• Safe during breast cancer treatment — no hormonal activity
• Available without prescription
How to use this
Apply 2-3 times weekly — not just before sex. Hyaluronic acid formulations preferred: Yes VM, SYLK, Replens MD. Apply inside the vaginal canal, not just at the entrance. Use at bedtime for best absorption. Can be used alongside local estrogen — they address different aspects of GSM.
🔴
Lubricants — for sexual comfort immediately
Strong evidence
Lubricants are used immediately before and during sexual activity to reduce friction and pain. They address the symptom in the moment rather than the underlying tissue — but for many women they provide the immediate relief that makes sexual activity possible while local estrogen builds its longer-term tissue effect.
Key points
• Silicone-based lubricants last longer than water-based and are particularly effective for GSM-related dryness
• Water-based lubricants are safe with condoms and most sex toys
• Oil-based lubricants are effective but degrade latex condoms
• Avoid glycerin-containing products — can alter vaginal pH and increase yeast infection risk
• Avoid products with parabens, fragrances, or flavourings — irritating to atrophied tissue
How to use this
For penetrative sex: apply silicone-based lubricant (Überlube, Sliquid Silk) to both partners and at the vaginal opening. Reapply during activity if needed. For solo arousal: water-based lubricants (YES WB, Sliquid H2O) are a cleaner option. Avoid petroleum jelly — it disrupts vaginal microbiome.
💊
Systemic HRT — and why local estrogen is often still needed
Strong evidence
Systemic HRT (transdermal estradiol) reaches the vaginal tissue through the bloodstream and provides some GSM protection. However, at standard doses, systemic HRT may not fully reverse established GSM — the local tissue concentration achieved may be insufficient for complete tissue restoration. Many women on systemic HRT still need local vaginal estrogen for urogenital symptoms specifically.
Key points
• Provides systemic estrogen that reaches vaginal tissue
• Sufficient for mild GSM prevention when started early in perimenopause
• For established or moderate-severe GSM, local vaginal estrogen is usually additionally needed
• Addresses the broader hormonal picture — sleep, mood, bone, cardiovascular
How to use this
If on systemic HRT and still experiencing vaginal dryness or dyspareunia, add local vaginal estrogen — this is appropriate and commonly needed. Tell your GP you remain symptomatic vaginally and request the addition of vaginal estradiol or estriol.
🔬
Laser and energy-based devices — emerging options
Mixed evidence
Fractional CO2 laser and Er:YAG laser treatments applied intravaginally stimulate collagen remodelling and tissue restoration in the vaginal walls. Several studies show improvement in GSM symptoms. They are not first-line — local estrogen has a stronger evidence base and is significantly cheaper — but they may be considered for women who cannot use local estrogen and have not responded to other measures.
Key points
• Some evidence for improvement in vaginal dryness, dyspareunia, and urinary symptoms
• Non-hormonal — relevant for women where all estrogen is contraindicated
• Effects last 12-18 months — requires repeat treatments
How to use this
Available privately through gynaecology and aesthetic clinics. Expensive (£500-1500 per treatment course). Not available on the NHS. Discuss with a gynaecologist. Not a first-line treatment — pursue local estrogen and moisturisers first.
GSM and breast cancer — the safety question answered
Local vaginal estrogen is safe for most women with breast cancer history
The most common reason women with breast cancer history are denied vaginal estrogen is concern about systemic absorption raising estrogen exposure. At standard doses (Vagifem 10 mcg, Ovestin 0.1%), blood estradiol levels remain within the postmenopausal range — below the threshold considered meaningful for breast cancer risk.
The British Menopause Society, the British Gynaecological Cancer Society, and the European Menopause and Andropause Society all state that low-dose local vaginal estrogen can be considered for women with breast cancer, particularly those not on aromatase inhibitors, on an individualised risk-benefit basis.
For women on aromatase inhibitors (anastrozole, letrozole, exemestane), which work specifically by blocking peripheral estrogen production, vaginal estrogen should be discussed with their oncologist — the interaction is relevant to their breast cancer treatment. Ospemifene and hyaluronic acid moisturisers are non-hormonal alternatives for this group.
What to say to your doctor
Raising GSM — a symptom most doctors don't ask about
"I have been experiencing vaginal dryness, burning, and painful sex since perimenopause began. I understand this is Genitourinary Syndrome of Menopause — driven by estrogen loss in vaginal tissue. I would like local vaginal estrogen prescribed. The NICE menopause guideline recommends it as first-line treatment."
"I am on systemic HRT but still experiencing vaginal dryness. I understand that systemic doses may be insufficient for full urogenital tissue restoration and I would like local vaginal estrogen added."
"I have a history of breast cancer and I understand that low-dose local vaginal estrogen may be appropriate for me. I would like to discuss the risk-benefit assessment with you."
Rose on this
"Vaginal dryness is the symptom most likely to be managed with silence, lubricants, and avoiding intimacy. It does not have to be. Local vaginal estrogen reverses the tissue changes that cause it — not temporarily, but structurally. The tissue actually gets thicker, the pH actually comes back down, the lubrication actually returns. This is not symptom management. It is tissue restoration. You deserve to know it exists and to ask for it."
From Rose
"Sex that does not hurt. Sitting without discomfort. Not planning every day around toilet access. These are things that come back with treatment. GSM is one of the most treatable menopause conditions — and one of the most undertreated. Start the conversation. Ask for the prescription. Give it three months. The improvement is real and it is yours to have."
What we do not know yet
?The minimum effective maintenance dose of local vaginal estrogen — whether twice-weekly is the optimal frequency or whether some women can maintain tissue health with less frequent use after initial restoration
?Whether starting local vaginal estrogen in early perimenopause (before significant tissue change has occurred) prevents GSM entirely or only delays it — prevention vs treatment timing is not well studied
?The long-term safety of low-dose vaginal estrogen in women on aromatase inhibitors — current guidance recommends oncologist discussion but definitive safety data is limited
Written by
Rose
Navigating perimenopause · Researcher · Founded rosemyfriend.com
Research basis
PubMed · Cochrane reviews · NICE guidelines · British Menopause Society · The Menopause Society
Read methodology →
Rose provides evidence-graded educational information — not medical advice. Always discuss health decisions with a qualified healthcare provider.
Full disclaimer ·
About Rose